The European Commission has approved a combination of an immunotherapy agent with a poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of certain patients with primary advanced or recurrent endometrial cancer. Imfinzi (durvalumab, AstraZeneca) plus chemotherapy as a first-line treatment followed by Lynparza (olaparib, AstraZeneca) plus Imfinzi was approved for patients with mismatch repair proficient …
